ALBO News and Press, Albireo Pharma Inc. From 06/30/22

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Biotech Focus Conference July 12-13, 2022. Ron Cooper, President and Chief Executive Officer,...

Four presentations highlight newest data from landmark Phase 3 PEDFIC 1 and PEDFIC 2 trials, largest studies completed in PFIC New analysis show potential for greater response and higher proportion of pruritus responders with dose escalation and consistent tolerability across do...

New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay ® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic parameters Long-term data from PEDFIC trials of Bylvay show dramat...

– Five abstracts accepted, long-term data confirmed durable efficacy with Bylvay™ (odevixibat), with demonstrated improvement in quality of life, growth, and sleep measurements, and hepatic biomarkers in children with all types of PFIC – Two abstracts descri...

– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat) – Three oral presentations discuss long-term safety, tolerability and improved quality of life, hepatic biochemical markers, sleep in children with PF...

BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer will be presenting at the following investor conferences: Willi...

– Six abstracts presented highlighting data on Bylvay TM (odevixibat) and effects on pruritus, serum bile acids, growth and sleep parameters – Pre-clinical study of systemic ASBT/NTCP inhibitors, shows potential of dual-acting ileal/kidney and liver bile ...

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright Global Life Science Conference May 23-26, 2022. Simon Harford, Chief Financial Officer, will...

Gainers: Applied UV (AUVI) +30%. Forge Global Holdings (FRGE) +29%. Jumia Technologies (JMIA) +27%. Sunlight Financial Holdings (SUNL) +26%. Blue Water Vaccines (BWV) +26%. Enthusiast Gaming Holdings (EGLX) +25%. BTCS (BTCS) +24%. Yellow (YELL) +22%. Marpai (MRAI) +21%. Losers: AutoWeb (AUTO)...

Albireo Pharma (NASDAQ:ALBO -19.9%) stock plunged on Tuesday after the company posted lower-than-expected quarterly revenue and wider-than-expected loss, hurt by fall in demand for skin treatment, Bylvay. Quarterly revenue rose 248.5% Y/Y to $6.83M, but missed analysts estimate by $...